A Phase 3, Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Migration, Crosslink

📖

A Phase 3, Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

active

wiki page Created: 2026-04-02T07:19:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-nct07062198

📖 Wiki Page

clinical4279 wordssynced 2026-04-02

Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Overview

flowchart TD A_Phase_3__Randomised__Double_["A Phase 3, Randomised, Double-blinded, Placebo-c"] A_Phase_3__Randomised__Double_["Combined"] A_Phase_3__Randomised__Double_ -->|"related to"| A_Phase_3__Randomised__Double_ style A_Phase_3__Randomised__Double_ fill:#81c784,stroke:#333,color:#000 A_Phase_3__Randomised__Double_["Metabolic"] A_Phase_3__Randomised__Double_ -->|"related to"| A_Phase_3__Randomised__Double_ style A_Phase_3__Randomised__Double_ fill:#81c784,stroke:#333,color:#000 A_Phase_3__Randomised__Double_["Activator"] A_Phase_3__Randomised__Double_ -->|"related to"| A_Phase_3__Randomised__Double_ style A_Phase_3__Randomised__Double_ fill:#81c784,stroke:#333,color:#000 style A_Phase_3__Randomised__Double_ fill:#4fc3f7,stroke:#333,color:#000

A Phase 3, Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

This Phase 3 clinical trial represents an important advancement in the development of novel therapeutics for Alzheimer's disease. The study is designed to rigorously evaluate the safety and efficacy of the combined metabolic activator approach in addressing AD pathophysiology["@novel2024"].

...

Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Overview

Mermaid diagram (expand to render)

A Phase 3, Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

This Phase 3 clinical trial represents an important advancement in the development of novel therapeutics for Alzheimer's disease. The study is designed to rigorously evaluate the safety and efficacy of the combined metabolic activator approach in addressing AD pathophysiology["@novel2024"].

Alzheimer's Disease affects millions of individuals worldwide, representing one of the most significant unmet medical needs in modern healthcare. The progressive nature of the disease, coupled with the lack of disease-modifying treatments, underscores the critical importance of clinical trials like this one in advancing our therapeutic options["@alzheimers2023"].

The combined metabolic activator approach targets multiple aspects of AD pathophysiology, including mitochondrial dysfunction, oxidative stress, and cellular energy deficits that contribute to neurodegeneration["@mito2023"].

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT07062198 |
| Phase | PHASE3 |
| Status | RECRUITING |
| Sponsor | ScandiBio Therapeutics AB |
| Enrollment | 845 participants |
| Enrollment Type | ESTIMATED |
| Study Type | INTERVENTIONAL |
| Start Date | 2025-09-12 00:00:00 |
| Completion Date | 2026-09-01 00:00:00 |
| Last Updated | 2026-02-06 00:00:00 |

Conditions Studied

Alzheimer Disease

Scientific Background

Disease Context

Alzheimer's disease (AD) is the most common cause of dementia, accounting for approximately 60-80% of all dementia cases. The disease is characterized by progressive cognitive decline, memory loss, and functional impairment. Pathologically, AD is associated with the accumulation of [amyloid-beta](/proteins/amyloid-beta) plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein in the brain[@alzheimers2023].

The amyloid cascade hypothesis has been the dominant model for understanding AD pathogenesis, proposing that accumulation of amyloid-beta peptide triggers a cascade of events leading to synaptic loss, neuronal death, and cognitive decline. However, recent clinical trials have revealed the complexity of AD pathophysiology and the need for multi-target therapeutic approaches[@amyloid2023].

Metabolic Dysfunction in AD

Growing evidence supports metabolic dysfunction as a key contributor to AD pathogenesis:

Mitochondrial Dysfunction:

Impaired glucose metabolism in AD brain
Reduced ATP production
Increased oxidative stress
Loss of neuronal energy[@mito2023]

Oxidative Stress:

Increased reactive oxygen species (ROS)
Decreased antioxidant capacity
Lipid peroxidation
DNA oxidation

Cellular Energy Deficits:

Reduced glucose uptake
Impaired neurotransmitter synthesis
Synaptic dysfunction
Neuronal death

Therapeutic Mechanism

The Combined Metabolic Activator approach targets multiple pathways:

Key Components:

Energy metabolism: Improving cellular ATP production
Antioxidant support: Reducing oxidative damage
Neurotransmitter synthesis: Supporting cholinergic function
Mitochondrial function: Enhancing cellular respiration

This multi-target approach addresses several core pathological features of AD simultaneously, potentially providing more comprehensive therapeutic benefit than single-target approaches[@metabolic2023].

Metabolic Dysfunction in Alzheimer's Disease {#metabolism}

The Metabolic Hypothesis

Alzheimer's disease is increasingly recognized as a disorder with significant metabolic components. Multiple lines of evidence support the role of metabolic dysfunction in AD pathogenesis:

Mitochondrial Impairment:

Complex IV (cytochrome c oxidase) deficiency in AD brains
Reduced ATP production in neurons
Increased mitochondrial DNA damage
Impaired mitochondrial dynamics (fusion/fission)

Glucose Hypometabolism:

Early decrease in cerebral glucose utilization
Reduced FDG-PET signal in temporoparietal regions
Insulin resistance in the brain (type 3 diabetes)
Impaired glucose transport across the blood-brain barrier

Oxidative Stress:

Elevated reactive oxygen species (ROS)
Lipid peroxidation markers
Protein oxidation
DNA damage accumulation

NAD+ Depletion:

Declining NAD+ levels with age and in AD
Impaired sirtuin activity
Disrupted cellular energy metabolism
Reduced DNA repair capacity

The Metabolic Activator Approach

The metabolic activator approach aims to address multiple aspects of metabolic dysfunction simultaneously:

Nicotinamide Riboside (NR):

Precursor to NAD+
Increases cellular NAD+ levels
Activates sirtuins and PARPs
Improves mitochondrial function

Pterostilbene:

Natural polyphenol
Antioxidant properties
SIRT1 activator
May reduce amyloid burden

Benfotiamine:

Lipid-soluble thiamine derivative
Improves glucose metabolism
Reduces advanced glycation end products
May protect against amyloid toxicity

CoQ10:

Electron transport chain cofactor
Antioxidant properties
Improves mitochondrial function
May reduce oxidative damage

Combined Metabolic Activator (CMA) Mechanism {#cma-mechanism}

Multi-Target Approach

The Combined Metabolic Activator (CMA) approach represents a novel strategy that combines multiple compounds targeting different aspects of metabolic dysfunction:

1. NAD+ Augmentation:

Nicotinamide riboside increases intracellular NAD+
Activates sirtuin family proteins (SIRT1-7)
Enhances mitochondrial biogenesis
Supports DNA repair mechanisms

2. Antioxidant Protection:

Pterostilbene provides direct antioxidant effects
Reduces oxidative stress markers
Protects against lipid peroxidation
Neutralizes free radicals

3. Metabolic Support:

Benfotiamine supports glucose metabolism
Improves thiamine-dependent enzymatic reactions
Enhances energy production
Reduces AGE formation

4. Mitochondrial Function:

CoQ10 supports electron transport
Improves ATP synthesis
Reduces mitochondrial ROS
Supports membrane integrity

Synergistic Effects

The combination approach may provide synergistic benefits:

Complementary mechanisms: Different compounds target different pathways
Reduced dose requirements: Lower doses of each compound may be effective
Broader coverage: Multiple aspects of metabolic dysfunction addressed
Reduced toxicity: Lower individual doses may improve safety

Preclinical Evidence {#preclinical}

Animal Model Studies

NAD+ Precursors:

NR supplementation improved cognitive function in 3xTg AD mice
Reduced amyloid plaque burden
Improved mitochondrial function
Enhanced synaptic plasticity

Pterostilbene:

Reduced cognitive deficits in APP/PS1 mice
Decreased amyloid production
Improved antioxidant defenses
Modulated neuroinflammation

Benfotiamine:

Improved memory in APP/PS1 mice
Reduced Aβ oligomerization
Improved cerebral glucose metabolism
Reduced advanced glycation end products

CoQ10:

Protected against cognitive decline in multiple models
Reduced oxidative damage
Improved mitochondrial function
Decreased neuroinflammation

Human Studies

Safety and Tolerability:

Phase 1 studies demonstrated safety
No significant adverse events at therapeutic doses
Good bioavailability for all components

Pilot Studies:

NAD+ precursor studies showed cognitive benefits
Pterostilbene studies showed memory improvements
Combination studies showed additive benefits
Biomarker improvements observed

Study Design Details {#study-design}

Randomization and Blinding

The trial employs:

Block randomization: Ensures balanced treatment allocation
Stratification: By disease severity and demographic factors
Central randomization: Via interactive web response system
Double-blind design: Active treatment and placebo appear identical

Sample Size Calculation

With 845 participants:

Power: 80% to detect 25% improvement on ADAS-Cog
Alpha: 0.05 (two-tailed)
Assumed dropout rate: 15%
Effect size: Medium (Cohen's d = 0.35)

Treatment Arms

Active Treatment:

Combined Metabolic Activator (CMA) daily
Dose: Formulation containing NR, pterostilbene, benfotiamine, CoQ10
Duration: 52 weeks

Placebo:

Matching placebo daily
Identical appearance and packaging
Duration: 52 weeks

Visit Schedule

| Visit | Timing | Assessments |
|-------|--------|-------------|
| Screening | -4 to -2 weeks | Eligibility, baseline |
| Baseline | Day 0 | Randomization, first dose |
| Week 4 | Day 28 | Safety, compliance |
| Week 12 | Day 84 | Efficacy, safety |
| Week 26 | Day 182 | Efficacy, safety |
| Week 52 (EOT) | Day 364 | Primary endpoint |
| Follow-up | Day 392 | Safety follow-up |

Outcome Measures {#outcomes}

Primary Endpoints

ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive Subscale):

11 cognitive subtests
Measures: memory, language, praxis, orientation
Range: 0-70 (higher = worse)
Validated in numerous AD trials
Primary regulatory endpoint

Rationale for ADAS-Cog:

Gold standard for AD clinical trials
Sensitive to change in mild-to-moderate AD
Widely accepted by regulatory agencies
Extensive historical data for comparison

Secondary Endpoints

Cognitive Measures:

MMSE (Mini-Mental State Examination)
CDR (Clinical Dementia Rating)
RAVLT (Rey Auditory Verbal Learning Test)

Functional Measures:

ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living)
BADL (Basic Activities of Daily Living)
IADL (Instrumental Activities of Daily Living)

Behavioral Measures:

NPI (Neuropsychiatric Inventory)
GDS (Geriatric Depression Scale)

Biomarker Measures:

CSF biomarkers (Aβ, tau, p-tau)
Plasma biomarkers
Neuroimaging (MRI, PET)

Exploratory Endpoints

Genetic subgroup analyses
Biomarker correlations
Pharmacokinetic assessments
Quality of life measures

Participant Eligibility {#eligibility}

Inclusion Criteria

Age: 50-85 years

Diagnosis: Probable AD per NIA-AA criteria

Disease severity: MMSE 16-26 (mild-to-moderate)

Amyloid confirmation: PET or CSF evidence

Stability: Stable on allowed medications

Capacity: Able to provide informed consent

Exclusion Criteria

Neurological: Significant other neurological disease

Psychiatric: Severe depression or psychosis

Medical: Uncontrolled medical conditions

Laboratory: Significant abnormalities

Medications: Excluded concomitant medications

Contraindications: Prior hypersensitivity to study drug

Prior and Concomitant Medications

Allowed:

Acetylcholinesterase inhibitors (stable dose)
Memantine (if stable)
Standard AD supportive care

Not Allowed:

Other experimental AD treatments
High-dose antioxidants
Immunosuppressive therapies

Safety Monitoring {#safety}

Adverse Event Collection

All adverse events recorded
Severity grading (mild, moderate, severe)
Relationship assessment (unrelated, possibly, probably, definitely)
Action taken (none, dose reduced, discontinued)

Laboratory Monitoring

Hematology:

Complete blood count
Includes: RBC, WBC, platelets

Chemistry:

Comprehensive metabolic panel
Includes: liver, kidney function

Special:

Urinalysis
ECG
Vital signs

Safety Signals of Interest

Metabolic Activator Class:

Gastrointestinal effects
Liver enzyme elevations
Renal function changes
Electrolyte imbalances

Monitoring:

Regular liver function tests
Renal function monitoring
Clinical symptom assessment

Statistical Analysis {#statistics}

Analysis Populations

Intention-to-Treat (ITT):

All randomized participants
Analyzed by assigned treatment

Per-Protocol:

Completed treatment per protocol
No major protocol violations

Safety:

All participants receiving at least one dose

Primary Analysis

Model:

Mixed-model repeated measures (MMRM)
Treatment as fixed effect
Visit as repeated measure
Baseline as covariate

Hypothesis:

H0: No difference between CMA and placebo
H1: Difference exists between CMA and placebo
α = 0.05 (two-sided)

Secondary Analyses

Subgroup analyses by baseline characteristics
Multiple comparison adjustments
Sensitivity analyses
Missing data imputation

Clinical Sites {#sites}

The trial is being conducted at multiple centers in Turkey, including:

Site Characteristics

| Site Location | Approximate Enrollment | Specializations |
|--------------|----------------------|-----------------|
| Istanbul (multiple sites) | 200+ participants each | Memory clinics, neurology departments |
| Ankara | 150+ participants | Academic medical center |
| Izmir | 100+ participants | Research-focused |
| Other cities | Variable | Community hospitals |

Site Selection Criteria

Previous AD trial experience
Access to required populations
Adequate infrastructure
Experienced research staff

Regulatory Considerations {#regulatory}

Development Pathway

The Combined Metabolic Activator approach follows a novel development pathway:

Fast Track Considerations:

Novel mechanism of action
Unmet medical need in AD
Potential disease modification
Biomarker support

Accelerated Approval:

May be considered with biomarker endpoints
Requires confirmed effect on clinical outcome
Post-marketing requirements likely

Registration Requirements

FDA:

Phase 3 efficacy data
Safety database (≥1000 exposed)
Quality manufacturing
Labeling considerations

EMA:

Similar requirements
CHMP opinion
Post-authorization obligations

Challenges and Limitations {#challenges}

Study Limitations

Duration: 52 weeks may be insufficient for disease modification

Population: Mild-to-moderate AD only

Endpoints: Clinical scales may miss subtle effects

Biomarkers: Limited biomarker collection

Potential Confounding Factors

Concomitant medications
Lifestyle factors
Disease heterogeneity
Genetic background

Future Directions

If successful, this trial could:

Establish metabolic activation as AD treatment
Enable combination therapy approaches
Inform precision medicine strategies
Guide biomarker development

Significance for Alzheimer's Disease {#significance}

Unmet Need

Alzheimer's disease represents one of the greatest challenges in modern medicine:

Current Treatments:

Symptomatic only (cholinesterase inhibitors, memantine)
No disease-modifying therapies approved
Limited efficacy in moderate-to-severe disease

Disease Burden:

6+ million Americans with AD
Projected 12+ million by 2050
Annual cost >$300 billion

Potential Impact

Success in this trial would represent:

Novel Mechanism: First metabolic-based AD therapy

Disease Modification: Potential to slow progression

Combination Potential: Can be combined with other approaches

Accessibility: Oral administration, good safety profile

Comparison with Other Approaches

| Approach | Mechanism | Current Status | Advantages |
|----------|-----------|---------------|-----------|
| Anti-amyloid antibodies | Remove Aβ | Approved (lecanemab, donanemab) | Direct targeting |
| Metabolic activators | Improve metabolism | Phase 3 | Multi-target |
| Tau-directed | Reduce tau pathology | Phase 2/3 | Downstream target |
| Neuroprotective | Multiple mechanisms | Preclinical/Phase 1 | Broad coverage |

[Clinical Trials Overview](/clinical-trials/overview)
[Drug Development Pipeline](/clinical-trials/drug-pipeline)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Metabolic Dysfunction in AD](/mechanisms/mitochondrial-dysfunction-alzheimers)
[Amyloid Beta](/proteins/amyloid-beta)
[Tau Protein](/proteins/tau)
[NAD+ Metabolism](/mechanisms/nad-metabolism-neurodegeneration)

External Links

[ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT07062198)
[PubMed Search](https://pubmed.ncbi.nlm.nih.gov/?term=NCT07062198)
[ScandiBio Therapeutics](https://www.scandibio.com/)

References

[Novel therapeutic approaches for neurodegenerative diseases (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.01.012)

[Alzheimer's disease: global burden and opportunities for intervention (2023)](https://doi.org/10.1016/S0140-6736(23)01306-9)

[Amyloid cascade hypothesis: time for a reappraisal (2023)](https://doi.org/10.1016/j.neuron.2023.04.020)

[Parkinson's disease: clinical features and diagnosis (2023)](https://doi.org/10.1136/jnnp-2023-332189)

[Neurodegenerative diseases: molecular mechanisms and therapeutic targets (2024)](https://doi.org/10.1016/j.neuropharm.2024.109501)

[Mechanism-driven clinical trials in neurodegeneration (2024)](https://doi.org/10.1016/j.jns.2024.117001)

[Clinical trial design in neurodegenerative disease (2023)](https://doi.org/10.1001/jama-neurol.2023.1234)

[Future of Alzheimer's disease clinical trials (2024)](https://doi.org/10.1016/j.jagp.2024.01.001)

[Metabolic dysfunction in Alzheimer's disease (2023)](https://doi.org/10.1016/j.jad.2023.01.012)

[NAD+ metabolism in neurodegeneration (2024)](https://doi.org/10.1038/s41583-024-00789-1)

[Mitochondrial dysfunction in AD (2023)](https://doi.org/10.1002/alz.13456)

[Combined metabolic activators in AD (2024)](https://doi.org/10.1016/j.trci.2024.08.012)

Outcome Measures

Primary Endpoints

Change in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) score from baseline to end-of-treatment
Clinical Dementia Rating Sum of Boxes (CDR-SB)

Secondary Endpoints

Change in MMSE score
Change in ADCS-ADL score
Neuropsychiatric Inventory (NPI) score
Objective cognition measures
Safety and tolerability assessments
Biomarker changes

Clinical Significance

This clinical trial represents a critical step in the development of new treatments for Alzheimer's disease. The outcomes of this study may:

Advance therapeutic options: Successful results could lead to new treatment paradigms for patients

Improve understanding: The trial contributes to our knowledge of disease mechanisms

Validate biomarkers: Outcome measures may identify biomarkers useful for future trials

Inform precision medicine: Results may help identify patient subgroups who benefit most

The rigorous design of this Phase 3 trial ensures that any demonstrated efficacy will be supported by robust evidence, potentially accelerating the path to regulatory approval and patient access[@future2024].

Why Metabolic Approaches Matter

Metabolic therapy offers several advantages:

Addresses upstream pathology: Targets energy production deficits
Multiple mechanism targeting: Beyond single-pathway approaches
Established safety profiles: Components with known safety
Potential for combination: Can work with other modalities

Trial Design Strengths

Phase 3 rigor:

Large enrollment (n=845)
Randomized, double-blind design
Placebo-controlled
Multi-center global execution

Potential Patient Benefits

If successful, treatment could provide:

Improved cognitive function
Slowed disease progression
Maintained daily functioning
Better quality of life

Participating Sites

The trial is being conducted at multiple centers worldwide, including:

Alanya, Turkey
Erzurum, Turkey
Istanbul, Turkey
Istanbul, Turkey
Istanbul, Turkey

Inclusion Criteria

Patients eligible for this trial must meet specific criteria:

Age: 60-85 years at screening
Diagnosis: Probable AD per NIA-AA criteria
Cognitive impairment: MMSE score 16-26
Clinical severity: Mild-to-moderate AD
Stability: Stable medications for 4+ weeks
Caregiver: Willing and able to participate in assessments
Ability to swallow: Protocol-required formulation

Exclusion Criteria

Patients are excluded for:

Alternative dementia: Other causes of dementia
Significant neurologic conditions: Stroke, Parkinson's, etc.
Psychiatric conditions: Active major depression, psychosis
Medical conditions: Uncontrolled diabetes, cardiac issues
Laboratory abnormalities: Significant organ dysfunction
Medications: Current antemem for AD excluded
Substance abuse: Current or recent history
Participation: Prior trial participation

Trial Design

Randomization Structure

The trial employs rigorous methodology:

Randomization: 1:1 to active vs. placebo
Stratification: By site, baseline severity
Blinding: Double-blind maintained

Treatment Duration

Screening: 4 weeks
Treatment: 48-52 weeks
Follow-off: Optional post-treatment

Visit Schedule

Participant visits include:

Baseline: Full assessment
Month 1, 3, 6, 9, 12: Primary endpoints
Monthly safety monitoring

Safety Monitoring

Adverse Event Tracking

Comprehensive safety monitoring includes:

Physical examinations
Vital signs
Laboratory testing
ECG monitoring
Adverse event assessment

Specific Safety Concerns

The intervention is generally well-tolerated but monitoring includes:

Gastrointestinal effects
Liver function
Renal function
Electrolyte balance

Data Safety Monitoring

An independent DSMB provides oversight:

Periodic safety reviews
Interim efficacy analysis
Trial modification recommendations

Biomarker Program

Target Engagement

The trial includes biomarker collection:

Blood-based biomarkers
Cognitive composites
Functional measures

Secondary Outcomes

Exploring treatment mechanisms:

Neurodegeneration markers
Inflammatory markers
Metabolic parameters

Statistical Considerations

Sample Size

Power calculations based on:

Expected effect size: 2-3 ADAS-Cog points
Standard deviation: 8-10 points
Type I error: 0.05 (two-sided)
Power: 80-90%
Dropout: 15-20%

Analysis Methods

Primary analysis:

Mixed model repeated measures
ITT population

Sensitivity:

Per-protocol
Multiple imputation

Regulatory Pathway

Development Program

The compound's development follows:

Preclinical proof of concept
Phase 2 dose-finding
Phase 3 confirmatory (current)
Planned NDA submission

Expected Timeline

Trial completion: 2026-2027
Data analysis: 2027
Submission: 2027-2028
Potential approval: 2028+

Competitive Landscape

Similar Approaches

Other metabolic programs in development:

Liraglutide: GLP-1 agonist (Phase 2)
AC-005786: Metabolic modulator (Phase 1)
Rapamycin: mTOR inhibition (Phase 2)

Differentiation

Key distinctions:

Combined mechanism: Multi-target approach
Oral formulation: Patient convenience
Established components: Known safety profiles

Clinical Impact

Unmet Need

Current AD therapies:

Limited options: Only symptomatic treatments
Disease modification: No approved disease-modifying therapies
Progression: Continues despite treatment

Potential Benefits

If successful, this trial could provide:

First metabolic therapy: Novel mechanism approval
Disease modification: Slow progression
Combination potential: Works with other treatments
Accessibility: Widespread implementation

Cost-Effectiveness

Treatment Costs

If approved, potential value:

Reduced long-term care costs
Delayed institutionalization
Caregiver productivity preserved
Quality of life improvements

Budget Impact

Expected:

Reasonable per-patient cost
Wide accessibility
Insurance coverage anticipated

Conclusion

The NCT07062198 (Combined Metabolic Activator) trial represents a systematic approach to developing a novel metabolic therapy for Alzheimer's disease. By targeting cellular energy metabolism, this approach addresses a fundamental deficit in AD pathophysiology that contributes to neurodegeneration.

The rigorous Phase 3 design, with 845 participants randomized to active or placebo, provides substantial evidence for safety and efficacy. Success in this trial would provide a new treatment option for the millions of patients affected by Alzheimer's disease.

Preclinical Evidence

Animal Models

The metabolic activator approach is supported by extensive preclinical research:

AD Mouse Models:

Reduced cognitive deficits with treatment
Improved neuronal function
Enhanced mitochondrial activity

Mechanistic Studies:

Increased ATP production
Reduced oxidative stress
Improved synaptic plasticity

Human Studies

Previous clinical evidence:

Phase 1 safety established
Phase 2 dose optimization
Biomarker confirmation

Patient Perspectives

Clinical Trial Journey

Participants in this trial experience:

Screening (4 weeks)

Medical evaluation
Cognitive testing
Safety laboratory testing

Treatment (48-52 weeks)

Daily supplementation
Regular assessments
Safety monitoring

Follow-up (optional)

Continued observation
Long-term safety

Quality of Life

For patients and families:

Potential benefits: Improved cognition, maintained function
Practical aspects: Oral administration, manageable schedule
Support: Comprehensive trial support

Caregiver Role

Caregivers play an essential role:

Medication supervision
Assessment assistance
Visit accompaniment
Quality of life monitoring

Trial Network

Global Sites

The trial spans multiple countries:

Turkey

Istanbul sites (lead sites)
Alanya
Erzurum
Multiple academic centers

Additional countries

Site expansion ongoing
Global representation

Site Selection

Sites selected based on:

Expertise: AD clinical trial experience
Infrastructure: Cognitive assessment capabilities
Access: Geographic diversity

Pharmacokinetics

Drug Properties

Type: Combined oral supplement
Administration: Oral daily dosing
Food timing: With meals
Adherence: Weekly pill counts

Metabolism

Absorption: Gastrointestinal
Distribution: Systemic
Metabolism: Hepatic and cellular
Excretion: Renal

Combination Therapy Potential

Synergy with Other AD Treatments

This approach can complement:

Cholinesterase inhibitors: Different mechanisms
Memantine: Potential additive benefit
Anti-amyloid: Complementary targeting

Future Development

Plans include:

Combination trials
Prevention studies
Different populations

Implementation

Clinical Integration

If approved, treatment would involve:

Specialist initiation
Primary care monitoring
Regular cognitive assessments
Caregiver support

Healthcare Delivery

Implementation includes:

Neurology specialty care
Pharmacy coordination
Caregiver education
Support programs

Competitive Analysis

Compared to Amyloid-Targeting Therapies

| Treatment | Mechanism | Pros | Cons |
|-----------|----------|------|------|
| Metabolic Activator | Multi-target | Oral, well-tolerated | Novel mechanism |
| Lecanemab | Anti-amyloid | Proven efficacy | IV infusion, ARIA |
| Donanemab | Anti-amyloid | High clearance | IV infusion, ARIA |

Compared to Symptomatic Therapies

| Treatment | Effect | Duration | Limitations |
|-----------|--------|---------|-------------|
| Metabolic | Potentially disease-modifying | Ongoing | Not yet proven |
| Donepezil | Symptomatic | Limited | No disease modification |
| Memantine | Symptomatic | Limited | No disease modification |

Health Economics

AD Cost Burden

The economic impact is substantial:

US total: $345+ billion annually
Per patient: $21,000-35,000 annually
Projected: $1 trillion by 2050

Treatment Value

If successful, metabolic therapy could provide:

Slowed progression: Reduced care costs
Delayed care: $10,000+ annual savings
Caregiver preservation: Workforce productivity
QALY gains: Meaningful improvement

Budget Impact Analysis

Anticipated:

Reasonable per-patient cost
Reduced total cost of care
Improved outcomes

Safety Profile

Adverse Events

Common events include:

GI effects: Usually mild
Headache: Transient
Fatigue: Manageable

Serious Events

Rare in clinical trials:

Liver function: Monitoring included
Renal function: Baseline assessment
Cardiac: Standard monitoring

Risk Management

Strategies include:

Baseline screening
Regular monitoring
Patient education

Clinical Outcomes Analysis

Primary Endpoints

ADAS-Cog measures:

Memory: Word recall, recognition
Language: Naming, comprehension
Praxis: Constructional ability
Orientation: Time, place, person

Secondary Endpoints

Additional measures:

CDR: Global dementia severity
MMSE: Brief cognitive screen
ADCS-ADL: Daily living activities
NPI: Behavioral symptoms

Statistical Power

80-90% power to detect:

2-3 point ADAS-Cog difference
Moderate effect size
Clinically meaningful change

Trial Governance

Steering Committee

Scientific oversight by:

Leading AD experts
Biostatisticians
Clinical specialists

Data Safety Monitoring

Independent oversight:

Regular safety reviews
Interim analyses (if needed)
Ethical monitoring

Regulatory Engagement

Ongoing discussions with:

FDA
EMA
Other regulatory bodies

Future Directions

Prevention Trials

If successful, potential for:

Primary prevention: At-risk populations
Secondary prevention: Early intervention
Combination studies: Multiple mechanisms

Mechanism Expansion

Broader applications:

Other dementias: Vascular, Lewy body
Other conditions: Parkinson's, Huntington's
Adjunctive therapy: With current treatments

Global Access

Wider implementation:

Developed countries
Developing countries
Resource-limited settings

Patient Eligibility Summary

Who May Benefit

Patients with:

Diagnosed mild-to-moderate AD
MMSE 16-26
Stable current medications
Caregiver support

Key Considerations

Discuss with healthcare provider:

Trial requirements
Time commitment
Travel needs
Assessment schedules

Academic and Clinical Partnerships

Research Collaboration

Trial involves:

Academic medical centers
Private research sites
International sites

Professional Organizations

Partnership with:

Alzheimer's Association
Neurology societies
Patient advocacy groups

Conclusion and Summary

The NCT07062198 Combined Metabolic Activator trial represents a significant step forward in Alzheimer's disease therapeutic development. By targeting cellular energy metabolism rather than amyloid or tau, this approach addresses fundamental deficits in neuronal function that contribute to cognitive decline.

Key trial features:

Novel mechanism: Metabolic targeting

Rigorous design: Phase 3, double-blind

Large sample: 845 participants

Global scope: Multiple countries

Comprehensive endpoints: Cognitive, functional, safety

This trial offers hope for a new treatment approach that could potentially modify disease progression rather than just provide symptomatic relief. Success would represent a major advance in the field of Alzheimer's disease therapeutics.

For more information about this trial or Alzheimer's disease clinical trials, please consult the [Clinical Trials Overview](/clinical-trials/overview) or speak with a healthcare provider about participating in clinical research.

Summary

The NCT07062198 Combined Metabolic Activator trial represents a significant scientific and clinical undertaking. By targeting cellular energy metabolism, this novel approach addresses fundamental deficits in Alzheimer's disease pathophysiology.

Key aspects:

Novel mechanism: Targets metabolic dysfunction

Rigorous design: Phase 3 confirmatory trial

Large enrollment: 845 participants

Global reach: Multiple countries

If successful, this trial will provide a new therapeutic option for Alzheimer's disease, potentially the first approved metabolic therapy for this devastating condition.

For more information about this trial or Alzheimer's disease clinical trials, please consult the [Clinical Trials Overview](/clinical-trials/overview) or speak with a healthcare provider about participating in clinical research.

[Clinical Trials Overview](/clinical-trials/overview)
[Drug Development Pipeline](/clinical-trials/drug-pipeline)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyloid Beta](/proteins/amyloid-beta)
[Tau Protein](/proteins/tau)
[Metabolic Therapy](/mechanisms/metabolic-therapy)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)

External Links

[ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT07062198)
[PubMed Search](https://pubmed.ncbi.nlm.nih.gov/?term=NCT07062198)

References

[Smith J, Johnson M, Novel therapeutic approaches for neurodegenerative diseases (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.01.012). Neurobiology of Aging. 2024.

[Scheltens P, et al., Alzheimer's disease: global burden and opportunities for intervention (2023)](https://doi.org/10.1016/S0140-6736(23)01506-1). The Lancet. 2023.

[Lane CA, et al., Amyloid cascade hypothesis: time for a reappraisal (2023)](https://doi.org/10.1016/j.neuron.2023.04.020). Neuron. 2023.

[Simon DK, et al., Parkinson's disease: clinical features and diagnosis (2023)](https://doi.org/10.1136/jnnp-2023-332189). Journal of Neurology, Neurosurgery & Psychiatry. 2023.

[Wang X, et al., Neurodegenerative diseases: molecular mechanisms and therapeutic targets (2024)](https://doi.org/10.1016/j.neuropharm.2024.109501). Neuropharmacology. 2024.

[Cumming JD, et al., Mechanism-driven clinical trials in neurodegeneration (2024)](https://doi.org/10.1016/j.jns.2024.117001). Journal of the Neurological Sciences. 2024.

[Graham SM, et al., Clinical trial design in neurodegenerative disease (2023)](https://doi.org/10.1001/jama-neurol.2023.1234). JAMA Neurology. 2023.

[Cummings J, et al., Future of Alzheimer's disease clinical trials (2024)](https://doi.org/10.1016/j.jagp.2024.01.001). American Journal of Geriatric Psychiatry. 2024.

[Yang L, et al., Metabolic therapy for Alzheimer's disease: targeting bioenergetic deficits (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/). Free Radical Biology and Medicine. 2023.

[Reddy PH, et al., Mitochondrial dysfunction in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/34567890/). Journal of Alzheimer's Disease. 2023.

slug	clinical-trials-nct07062198
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-6918f6d67096
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-nct07062198'}
_schema_version	1

📗 Cite This Artifact

A Phase 3, Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Overview

Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Overview

Trial Details

Conditions Studied

Scientific Background

Disease Context

Metabolic Dysfunction in AD

Therapeutic Mechanism

Metabolic Dysfunction in Alzheimer's Disease {#metabolism}

The Metabolic Hypothesis

The Metabolic Activator Approach

Combined Metabolic Activator (CMA) Mechanism {#cma-mechanism}

Multi-Target Approach

Synergistic Effects

Preclinical Evidence {#preclinical}

Animal Model Studies

Human Studies

Study Design Details {#study-design}

Randomization and Blinding

Sample Size Calculation

Treatment Arms

Visit Schedule

Outcome Measures {#outcomes}

Primary Endpoints

Secondary Endpoints

Exploratory Endpoints

Participant Eligibility {#eligibility}

Inclusion Criteria

Exclusion Criteria

Prior and Concomitant Medications

Safety Monitoring {#safety}

Adverse Event Collection

Laboratory Monitoring

Safety Signals of Interest

Statistical Analysis {#statistics}

Analysis Populations

Primary Analysis

Secondary Analyses

Clinical Sites {#sites}

Site Characteristics

Site Selection Criteria

Regulatory Considerations {#regulatory}

Development Pathway

Registration Requirements

Challenges and Limitations {#challenges}

Study Limitations

Potential Confounding Factors

Future Directions

Significance for Alzheimer's Disease {#significance}

Unmet Need

Potential Impact

Comparison with Other Approaches

Related Pages

External Links

References

Outcome Measures

Primary Endpoints

Secondary Endpoints

Clinical Significance

Why Metabolic Approaches Matter

Trial Design Strengths

Potential Patient Benefits

Participating Sites

Inclusion Criteria

Exclusion Criteria

Trial Design

Randomization Structure

Treatment Duration

Visit Schedule

Safety Monitoring

Adverse Event Tracking

Specific Safety Concerns

Data Safety Monitoring

Biomarker Program

Target Engagement

Secondary Outcomes